BlessedCyrus
2021-05-21
Tell me your opinion about this news...
India and Pfizer at impasse over vaccine indemnity demand -sources<blockquote>印度和辉瑞在疫苗赔偿要求上陷入僵局——消息人士</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":139379133,"tweetId":"139379133","gmtCreate":1621596403122,"gmtModify":1634187788852,"author":{"id":3570768873457401,"idStr":"3570768873457401","authorId":3570768873457401,"authorIdStr":"3570768873457401","name":"BlessedCyrus","avatar":"https://static.tigerbbs.com/eb301da67b54f9fd5d2fd2626595aada","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Tell me your opinion about this news...</p></body></html>","htmlText":"<html><head></head><body><p>Tell me your opinion about this news...</p></body></html>","text":"Tell me your opinion about this news...","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/139379133","repostId":2137906383,"repostType":2,"repost":{"id":"2137906383","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1621591288,"share":"https://www.laohu8.com/m/news/2137906383?lang=zh_CN&edition=full","pubTime":"2021-05-21 18:01","market":"us","language":"en","title":"India and Pfizer at impasse over vaccine indemnity demand -sources<blockquote>印度和辉瑞在疫苗赔偿要求上陷入僵局——消息人士</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2137906383","media":"Reuters","summary":"By Neha Arora and Carl O'Donnell NEW DELHI/NEW YORK, May 21 (Reuters) - Pfizer and the Indian g","content":"<p><html><body>By Neha Arora and Carl O'Donnell</p><p><blockquote><html><body>作者：内哈·阿罗拉和卡尔·安东内尔</body></html></blockquote></p><p> NEW DELHI/NEW YORK, May 21 (Reuters) - Pfizer and the Indian government are at loggerheads over a demand by the U.S. drugmaker for legal protection from any claims linked to the use of its COVID-19 vaccine in <a href=\"https://laohu8.com/S/AONE\">one</a> of the world's biggest markets, two sources told Reuters.</p><p><blockquote>路透新德里/纽约5月21日-辉瑞和印度政府就这家美国制药商要求提供法律保护，免受与其在印度使用其COVID-19疫苗有关的任何索赔的问题发生争执。<a href=\"https://laohu8.com/S/AONE\">一</a>两位消息人士告诉路透社。</blockquote></p><p> India has not given any manufacturer of a COVID-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States.</p><p><blockquote>印度没有向任何新冠肺炎疫苗制造商赔偿任何严重副作用的赔偿费用，这是辉瑞在许多已经广泛推广其疫苗的国家获得的条件，包括英国和美国。</blockquote></p><p> \"The whole problem with Pfizer is the indemnity bond. Why should we sign it?\" an Indian government source with direct knowledge of the matter told Reuters.</p><p><blockquote>“辉瑞的整个问题就是赔偿保证金。我们为什么要签署它？”一名直接了解此事的印度政府消息人士告诉路透社。</blockquote></p><p> \"If something happens, a patient dies, we will not be able to question them (Pfizer). If somebody challenges in a court of law, the central government will be responsible for everything, not the company,\" the source added.</p><p><blockquote>“如果发生什么事情，患者死亡，我们将无法质疑他们（辉瑞）。如果有人在法庭上质疑，中央政府将对一切负责，而不是公司，”消息人士补充道。</blockquote></p><p> Pfizer and India's health ministry did not reply to Reuters requests for comment on Friday.</p><p><blockquote>辉瑞和印度卫生部周五没有回复路透社的置评请求。</blockquote></p><p> The second source said Pfizer was not going to change its position on the indemnity issue.</p><p><blockquote>第二位消息人士称，辉瑞不会改变其在赔偿问题上的立场。</blockquote></p><p> Both sources declined to be named as they were not authorised to talk to the media.</p><p><blockquote>两位消息人士都拒绝透露姓名，因为他们无权接受媒体采访。</blockquote></p><p> LOCAL TRIAL</p><p><blockquote>本地试验</blockquote></p><p> India, which is facing a shortage of shots as coronavirus cases soar, pledged last month to fast-track approvals for overseas vaccine makers including Pfizer, Moderna and Johnson and Johnson . </p><p><blockquote>随着冠状病毒病例激增，印度正面临疫苗短缺的问题，印度上个月承诺快速批准辉瑞、Moderna和强生等海外疫苗制造商。</blockquote></p><p> However, none have since sought permission from India's drug regulator to sell their vaccine in the country, which has a population of 1.35 billion. </p><p><blockquote>然而，此后没有一家公司寻求印度药品监管机构的许可，在这个拥有13.5亿人口的国家销售疫苗。</blockquote></p><p> The second source said that the other issue being discussed between Pfizer and New Delhi was the Indian government's insistence on a local trial for any vaccine approval. </p><p><blockquote>第二位消息人士称，辉瑞和新德里正在讨论的另一个问题是印度政府坚持在当地进行任何疫苗批准试验。</blockquote></p><p> Pfizer withdrew its application for emergency use authorisation for the vaccine developed with Germany's BioNTech</p><p><blockquote>辉瑞撤回与德国BioNTech开发的疫苗的紧急使用授权申请</blockquote></p><p> in February after India insisted on such a trial.</p><p><blockquote>在印度坚持进行这样的审判之后。</blockquote></p><p> But three other shots on sale in India, developed by AstraZeneca , Russia's Sputnik V and Bharat Biotech in collaboration with state-run Indian Council of Medical Research, have completed the small-scale safety trials.</p><p><blockquote>但在印度销售的另外三种疫苗，由阿斯利康、俄罗斯Sputnik V和Bharat Biotech与国营的印度医学研究委员会合作开发，已经完成了小规模安全试验。</blockquote></p><p> Albert Bourla, Pfizer's chief executive said on May 4 that he was hopeful that the government would change its policy of local trials and that a path to delivering the drugmaker's shots in India could be found. </p><p><blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)5月4日表示，他希望政府能够改变当地试验的政策，并找到在印度提供该制药商疫苗的途径。</blockquote></p><p> A third source told Reuters that India's foreign minister would visit the United States this month or in early June to try and address Pfizer's concerns and ease exports of vaccine raw materials to India. </p><p><blockquote>第三名消息人士告诉路透社，印度外交部长将于本月或6月初访问美国，试图解决辉瑞的担忧，并缓解对印度的疫苗原材料出口。</blockquote></p><p> The Indian foreign ministry did not immediately respond to a request for comment. </p><p><blockquote>印度外交部没有立即回应置评请求。</blockquote></p><p> (Reporting by Neha Arora and Carl O'Donnell; Additional reporting by Rupam Jain; Editing by Krishna N. Das and Alexander Smith)</p><p><blockquote>（Neha Arora和Carl O'Donnell报道；Rupam Jain补充报道；Krishna N.Das和Alexander Smith编辑）</blockquote></p><p>((neha.dasgupta@tr.com;))</p><p><blockquote>((neha.dasgupta@tr.com;))</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>India and Pfizer at impasse over vaccine indemnity demand -sources<blockquote>印度和辉瑞在疫苗赔偿要求上陷入僵局——消息人士</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIndia and Pfizer at impasse over vaccine indemnity demand -sources<blockquote>印度和辉瑞在疫苗赔偿要求上陷入僵局——消息人士</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2021-05-21 18:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><body>By Neha Arora and Carl O'Donnell</p><p><blockquote><html><body>作者：内哈·阿罗拉和卡尔·安东内尔</body></html></blockquote></p><p> NEW DELHI/NEW YORK, May 21 (Reuters) - Pfizer and the Indian government are at loggerheads over a demand by the U.S. drugmaker for legal protection from any claims linked to the use of its COVID-19 vaccine in <a href=\"https://laohu8.com/S/AONE\">one</a> of the world's biggest markets, two sources told Reuters.</p><p><blockquote>路透新德里/纽约5月21日-辉瑞和印度政府就这家美国制药商要求提供法律保护，免受与其在印度使用其COVID-19疫苗有关的任何索赔的问题发生争执。<a href=\"https://laohu8.com/S/AONE\">一</a>两位消息人士告诉路透社。</blockquote></p><p> India has not given any manufacturer of a COVID-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States.</p><p><blockquote>印度没有向任何新冠肺炎疫苗制造商赔偿任何严重副作用的赔偿费用，这是辉瑞在许多已经广泛推广其疫苗的国家获得的条件，包括英国和美国。</blockquote></p><p> \"The whole problem with Pfizer is the indemnity bond. Why should we sign it?\" an Indian government source with direct knowledge of the matter told Reuters.</p><p><blockquote>“辉瑞的整个问题就是赔偿保证金。我们为什么要签署它？”一名直接了解此事的印度政府消息人士告诉路透社。</blockquote></p><p> \"If something happens, a patient dies, we will not be able to question them (Pfizer). If somebody challenges in a court of law, the central government will be responsible for everything, not the company,\" the source added.</p><p><blockquote>“如果发生什么事情，患者死亡，我们将无法质疑他们（辉瑞）。如果有人在法庭上质疑，中央政府将对一切负责，而不是公司，”消息人士补充道。</blockquote></p><p> Pfizer and India's health ministry did not reply to Reuters requests for comment on Friday.</p><p><blockquote>辉瑞和印度卫生部周五没有回复路透社的置评请求。</blockquote></p><p> The second source said Pfizer was not going to change its position on the indemnity issue.</p><p><blockquote>第二位消息人士称，辉瑞不会改变其在赔偿问题上的立场。</blockquote></p><p> Both sources declined to be named as they were not authorised to talk to the media.</p><p><blockquote>两位消息人士都拒绝透露姓名，因为他们无权接受媒体采访。</blockquote></p><p> LOCAL TRIAL</p><p><blockquote>本地试验</blockquote></p><p> India, which is facing a shortage of shots as coronavirus cases soar, pledged last month to fast-track approvals for overseas vaccine makers including Pfizer, Moderna and Johnson and Johnson . </p><p><blockquote>随着冠状病毒病例激增，印度正面临疫苗短缺的问题，印度上个月承诺快速批准辉瑞、Moderna和强生等海外疫苗制造商。</blockquote></p><p> However, none have since sought permission from India's drug regulator to sell their vaccine in the country, which has a population of 1.35 billion. </p><p><blockquote>然而，此后没有一家公司寻求印度药品监管机构的许可，在这个拥有13.5亿人口的国家销售疫苗。</blockquote></p><p> The second source said that the other issue being discussed between Pfizer and New Delhi was the Indian government's insistence on a local trial for any vaccine approval. </p><p><blockquote>第二位消息人士称，辉瑞和新德里正在讨论的另一个问题是印度政府坚持在当地进行任何疫苗批准试验。</blockquote></p><p> Pfizer withdrew its application for emergency use authorisation for the vaccine developed with Germany's BioNTech</p><p><blockquote>辉瑞撤回与德国BioNTech开发的疫苗的紧急使用授权申请</blockquote></p><p> in February after India insisted on such a trial.</p><p><blockquote>在印度坚持进行这样的审判之后。</blockquote></p><p> But three other shots on sale in India, developed by AstraZeneca , Russia's Sputnik V and Bharat Biotech in collaboration with state-run Indian Council of Medical Research, have completed the small-scale safety trials.</p><p><blockquote>但在印度销售的另外三种疫苗，由阿斯利康、俄罗斯Sputnik V和Bharat Biotech与国营的印度医学研究委员会合作开发，已经完成了小规模安全试验。</blockquote></p><p> Albert Bourla, Pfizer's chief executive said on May 4 that he was hopeful that the government would change its policy of local trials and that a path to delivering the drugmaker's shots in India could be found. </p><p><blockquote>辉瑞首席执行官阿尔伯特·布尔拉(Albert Bourla)5月4日表示，他希望政府能够改变当地试验的政策，并找到在印度提供该制药商疫苗的途径。</blockquote></p><p> A third source told Reuters that India's foreign minister would visit the United States this month or in early June to try and address Pfizer's concerns and ease exports of vaccine raw materials to India. </p><p><blockquote>第三名消息人士告诉路透社，印度外交部长将于本月或6月初访问美国，试图解决辉瑞的担忧，并缓解对印度的疫苗原材料出口。</blockquote></p><p> The Indian foreign ministry did not immediately respond to a request for comment. </p><p><blockquote>印度外交部没有立即回应置评请求。</blockquote></p><p> (Reporting by Neha Arora and Carl O'Donnell; Additional reporting by Rupam Jain; Editing by Krishna N. Das and Alexander Smith)</p><p><blockquote>（Neha Arora和Carl O'Donnell报道；Rupam Jain补充报道；Krishna N.Das和Alexander Smith编辑）</blockquote></p><p>((neha.dasgupta@tr.com;))</p><p><blockquote>((neha.dasgupta@tr.com;))</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","BNTX":"BioNTech SE","JNJ":"强生"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2137906383","content_text":"By Neha Arora and Carl O'Donnell NEW DELHI/NEW YORK, May 21 (Reuters) - Pfizer and the Indian government are at loggerheads over a demand by the U.S. drugmaker for legal protection from any claims linked to the use of its COVID-19 vaccine in one of the world's biggest markets, two sources told Reuters. India has not given any manufacturer of a COVID-19 vaccine indemnity against the costs of compensation for any severe side effects, which is a condition Pfizer has obtained in many countries where its shots have already been widely rolled out, including Britain and the United States. \"The whole problem with Pfizer is the indemnity bond. Why should we sign it?\" an Indian government source with direct knowledge of the matter told Reuters. \"If something happens, a patient dies, we will not be able to question them (Pfizer). If somebody challenges in a court of law, the central government will be responsible for everything, not the company,\" the source added. Pfizer and India's health ministry did not reply to Reuters requests for comment on Friday. The second source said Pfizer was not going to change its position on the indemnity issue. Both sources declined to be named as they were not authorised to talk to the media. LOCAL TRIAL India, which is facing a shortage of shots as coronavirus cases soar, pledged last month to fast-track approvals for overseas vaccine makers including Pfizer, Moderna and Johnson and Johnson . However, none have since sought permission from India's drug regulator to sell their vaccine in the country, which has a population of 1.35 billion. The second source said that the other issue being discussed between Pfizer and New Delhi was the Indian government's insistence on a local trial for any vaccine approval. Pfizer withdrew its application for emergency use authorisation for the vaccine developed with Germany's BioNTech in February after India insisted on such a trial. But three other shots on sale in India, developed by AstraZeneca , Russia's Sputnik V and Bharat Biotech in collaboration with state-run Indian Council of Medical Research, have completed the small-scale safety trials. Albert Bourla, Pfizer's chief executive said on May 4 that he was hopeful that the government would change its policy of local trials and that a path to delivering the drugmaker's shots in India could be found. A third source told Reuters that India's foreign minister would visit the United States this month or in early June to try and address Pfizer's concerns and ease exports of vaccine raw materials to India. The Indian foreign ministry did not immediately respond to a request for comment. (Reporting by Neha Arora and Carl O'Donnell; Additional reporting by Rupam Jain; Editing by Krishna N. Das and Alexander Smith)((neha.dasgupta@tr.com;))","news_type":1,"symbols_score_info":{"PFE":1,"MRNA":0.9,"JNJ":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":481,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":33,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/139379133"}
精彩评论